CCN3 - A key regulator of the hematopoietic compartment

Blood Reviews

Volumn 23, Issue 2, 2009, Pages 79-85

  McCallum, L ^a   Irvine, A E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Bone marrow microenvironment; CCN3; Chronic Myeloid Leukemia; Hematopoiesis; stem cell signaling

Indexed keywords

BCR ABL PROTEIN; BONE MORPHOGENETIC PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; NOTCH RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADRENAL CORTEX TUMOR; ARTICLE; BONE CANCER; BONE MARROW CELL; CANCER INHIBITION; CELL EXPANSION; CELL LINEAGE; CELL MATURATION; CELL TYPE; CHRONIC MYELOID LEUKEMIA; GLIOBLASTOMA; GROWTH REGULATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; MELANOMA; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN VARIANT; STEM CELL;

AMINO ACID SEQUENCE; HEMATOPOIETIC STEM CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NEPHROBLASTOMA OVEREXPRESSED PROTEIN;

EID: 60849137834     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.07.002     Document Type: Article

References (56)

1. Thibout H., Martinerie C., Creminon C., et al. Characterization of human NOV in biological fluids: an enzyme immunoassay for the quantification of human NOV in sera from patients with diseases of the adrenal gland and of the nervous system. J Clin Endocrinol Metab 88 (2003) 327-336
2. Planque N., and Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 3 (2003) 15
3. Grzeszkiewicz T.M., Lindner V., Chen N., Lam S.C., and Lau L.F. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans. Endocrinology 143 (2002) 1441-1450
4. Leu S.J., Lam S.C., and Lau L.F. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem 277 (2002) 46248-46255
5. Brigstock D.R. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 5 (2002) 153-165
6. Kubota S., and Takigawa M. Role of CCN2/CTGF/Hcs24 in bone growth. Int Rev Cytol 257 (2007) 1-41
7. Takigawa M., Nakanishi T., Kubota S., and Nishida T. Role of CTGF/HCS24/ecogenin in skeletal growth control. J Cell Physiol 194 (2003) 256-266
8. Xie D., Nakachi K., Wang H., Elashoff R., and Koeffler H.P. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61 (2001) 8917-8923
9. Tsai M.S., Bogart D.F., Castaneda J.M., Li P., and Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21 (2002) 8178-8185
10. Davies S.R., Watkins G., Mansel R.E., and Jiang W.G. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol 14 (2007) 1909-1918
11. Banerjee S., Sengupta K., Saxena N.K., Dhar K., and Banerjee S.K. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res 3 (2005) 151-162
12. Zhang Y., Pan Q., Zhong H., Merajver S.D., and Kleer C.G. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res 7 (2005) R1080-R1089
13. Kleer C.G., Zhang Y., and Merajver S.D. CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs 185 (2007) 95-99
14. French D.M., Kaul R.J., D'Souza A.L., et al. WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol 165 (2004) 855-867
15. Dhar G., Mehta S., Banerjee S., et al. Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition. Cancer Lett 254 (2007) 63-70
16. Bleau A.M., Planque N., Lazar N., et al. Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation. J Cell Biochem 101 (2007) 1475-1491
17. Planque N., Long Li C., Saule S., Bleau A.M., and Perbal B. Nuclear addressing provides a clue for the transforming activity of amino-truncated CCN3 proteins. J Cell Biochem 99 (2006) 105-116
18. Sakamoto K., Yamaguchi S., Ando R., et al. The nephroblastoma overexpressed gene (NOV/CCN3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J Biol Chem 277 (2002) 29399-29405
19. Lin C.G., Chen C.C., Leu S.J., Grzeszkiewicz T.M., and Lau L.F. Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem 280 (2005) 8229-8237
20. Perbal B., Martinerie C., Sainson R., Werner M., He B., and Roizman B. The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc Natl Acad Sci USA 96 (1999) 869-874
21. Minamizato T., Sakamoto K., Liu T., et al. CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways. Biochem Biophys Res Commun 354 (2007) 567-573
22. Fu C.T., Bechberger J.F., Ozog M.A., Perbal B., and Naus C.C. CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J Biol Chem 279 (2004) 36943-36950
23. Perbal B. New insight into CCN3 interactions-nuclear CCN3: fact or fantasy?. Cell Commun Signal 4 (2006) 6-13
24. Subramaniam M.M., Lazar N., Navarro S., Perbal B., and Llombart-Bosch A. Expression of CCN3 protein in human Wilms' tumors: immunohistochemical detection of CCN3 variants using domain-specific antibodies. Virchows Arch 452 (2008) 33-39
25. McCallum L., Price S., Planque N., et al. A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108 (2006) 1716-1723
26. Duncan A.W., Rattis F.M., DiMascio L.N., et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 6 (2005) 314-322
27. Eckfeldt C.E., Mendenhall E.M., Flynn C.M., et al. Functional analysis of human hematopoietic stem cell gene expression using zebrafish. PLoS Biol 3 (2005) 1449-1458
28. Gupta R., Hong D., Iborra F., Sarno S., and Enver T. NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells. Science 316 (2007) 590-593
29. Djouad F., Delorme B., Maurice M., et al. Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes. Arthritis Res Ther 9 (2007) R33
30. Yu C., Le A.T., Yeger H., Perbal B., and Alman B.A. NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia. J Pathol 201 (2003) 609-615
31. Shindo K., Kawashima N., Sakamoto K., et al. Osteogenic differentiation of the mesenchymal progenitor cells, Kusa is suppressed by Notch signaling. Exp Cell Res 290 (2003) 370-380
32. Calhabeu F., Lafont J., Le Dreau G., et al. NOV/CCN3 impairs muscle cell commitment and differentiation. Exp Cell Res 312 (2006) 1876-1889
33. Lin C.G., Leu S.J., Chen N., et al. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem 278 (2003) 24200-24208
34. Gong J.K. Endosteal marrow: a rich source of hematopoietic stem cells. Science 199 (1978) 1443-1445
35. Lord B.I., Testa N.G., and Hendry J.H. The relative spatial distributions of CFUs and CFUc in the normal mouse femur. Blood 46 (1975) 65-72
36. Calvi L.M. Osteoblastic activation in the hematopoietic stem cell niche. Ann NY Acad Sci 1068 (2006) 477-488
37. Parmar K., Mauch P., Vergilio J.A., Sackstein R., and Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104 (2007) 5431-5436
38. Karanu F.N., Yuefei L., Gallacher L., Sakano S., and Bhatia M. Differential response of primitive human CD34- and CD34+ hematopoietic cells to the Notch ligand Jagged-1. Leukemia 17 (2003) 1366-1374
39. Aster J.C., Pear W.S., and Blacklow S.C. Notch Signaling in Leukemia. Annu Rev Pathol 3 (2008) 587-613
40. Zweidler-McKay P.A., He Y., Xu L., et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 106 (2005) 3898-3906
41. Sakamoto K., Ohara O., Takagi M., Takeda S., and Katsube K. Intracellular cell-autonomous association of Notch and its ligands: a novel mechanism of Notch signal modification. Dev Biol 241 (2002) 313-326
42. Henning K., Heering J., Schwanbeck R., et al. Notch1 activation reduces proliferation in the multipotent hematopoietic progenitor cell line FDCP-mix through a p.53-dependent pathway but Notch1 effects on myeloid and erythroid differentiation are independent of p.53. Cell Death Differ 15 (2008) 398-407
43. Maillard I., Koch U., Dumortier A., et al. Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell 2 (2008) 356-366
44. Zhang J.L., Huang Y., Qiu L.Y., Nickel J., and Sebald W. von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms. J Biol Chem 282 (2007) 20002-20014
45. Parisi M.S., Gazzerro E., Rydziel S., and Canalis E. Expression and regulation of CCN genes in murine osteoblasts. Bone 38 (2006) 671-677
46. Fukunaga-Kalabis M., Martinez G., Liu Z.J., et al. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol 175 (2006) 563-569
47. Fukunaga-Kalabis M., Martinez G., Telson S.M., et al. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27 (2008) 2552-2560
48. Sin W.C., Bechberger J.F., Rushlow W.J., and Naus C.C. Dose-dependent differential upregulation of CCN1/Cyr61 and CCN3/NOV by the gap junction protein Connexin43 in glioma cells. J Cell Biochem 103 (2008) 1772-1782
49. Fu C.T., Bechberger J.F., Ozog M.A., Perbal B., and Naus C.C. CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J Biol Chem 279 (2004) 36943-36950
50. Gupta N., Wang H., McLeod T.L., et al. Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol Pathol 54 (2001) 293-299
51. Li W.X., Martinerie C., Zumkeller W., Westphal M., and Perbal B. Differential expression of novH and CTGF in human glioma cell lines. Mol Pathol 49 (1996) 91-97
52. Martinerie C., Gicquel C., Louvel A., Laurent M., Schofield P.N., and Le Bouc Y. Altered expression of novH is associated with human adrenocortical tumorigenesis. J Clin Endocrinol Metab 86 (2001) 3929-3940
53. Manara M.C., Perbal B., Benini S., et al. The expression of CCN3(NOV) gene in musculoskeletal tumors. Am J Pathol 160 (2002) 849-859
54. Benini S., Perbal B., Zambelli D., et al. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24 (2005) 4349-4361
55. Perbal B., Zuntini M., Zambelli D., et al. Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res 14 (2008) 701-709
56. Maillard M., Cadot B., Ball R.Y., et al. Differential expression of the CCN3 (NOV) proto-oncogene in human prostate cell lines and tissues. Mol Pathol 54 (2001) 275-280